Literature DB >> 20937623

Serum procalcitonin does not differentiate between infection and disease flare in patients with systemic lupus erythematosus.

J P Lanoix1, A M Bourgeois, J Schmidt, J Desblache, V Salle, A Smail, J C Mazière, F Betsou, G Choukroun, P Duhaut, J P Ducroix.   

Abstract

Systemic erythematosus lupus (SLE) is a common autoimmune disease. Disease flares may mimic infection with fever, inflammatory syndrome and chills, sometimes resulting in a difficult differential diagnosis. Elevated serum procalcitonin (PCT) levels have been reported to be predictive of bacterial infections, but with conflicting results. The value of serum procalcitonin has not been assessed in large series of SLE. We aimed to describe the distribution of PCT levels in SLE patients with and without flares, to assess the factors associated with increased PCT levels, and to determine the positive and negative predictive values of increased PCT for bacterial infection in SLE patients. Hospitalized SLE patients were included in a retrospective study. Serum PCT had been assayed, or a serum sample had been frozen on admission, before treatment modification. Serum PCT, measured by an automated immunofluorometric assay, and SLEDAI were assessed at the same time. Some 53 women (median age: 33.7 years, range 16-76) and seven men (median age: 52.5 years ± 19) were included. The median SLEDAI for patients with flare (n = 16, 28%) was 2 (range: 0-29). Five patients (8%) had systemic infection. Only one patient had increased PCT levels. Men had significantly higher PCT levels than women (0.196 ± 0.23 versus 0.066 ± 0.03, p < 0.01) and a significant correlation was observed between PCT, age, erythrocyte sedimentation rate, and C-reactive protein. We conclude that PCT levels were within the normal range in infected and non-infected SLE patients and there was no ability to differentiate SLE patients with or without bacterial infection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20937623     DOI: 10.1177/0961203310378862

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  14 in total

Review 1.  Validation of new biomarkers in systemic autoimmune diseases.

Authors:  Maria G Tektonidou; Michael M Ward
Journal:  Nat Rev Rheumatol       Date:  2011-11-01       Impact factor: 20.543

2.  Procalcitonin kinetics: a reliable tool for diagnosis and monitoring of the course of bacterial infection in critically ill patients with autoimmune diseases.

Authors:  Yan Shi; Xi Rui
Journal:  Intensive Care Med       Date:  2013-09-27       Impact factor: 17.440

Review 3.  Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review.

Authors:  Ilaria Serio; Laurent Arnaud; Alexis Mathian; Pierre Hausfater; Zahir Amoura
Journal:  Clin Rheumatol       Date:  2014-07-27       Impact factor: 2.980

4.  Evaluation of serum procalcitonin and C-reactive protein levels as biomarkers of Henoch-Schönlein purpura in pediatric patients.

Authors:  Xu Teng; Yang Wang; Nan Lin; Mei Sun; Jie Wu
Journal:  Clin Rheumatol       Date:  2014-10-03       Impact factor: 2.980

5.  [Immune diagnostics in rheumatology].

Authors:  R Gruber; S Borgmann
Journal:  Z Rheumatol       Date:  2014-08       Impact factor: 1.372

6.  Levels of serum procalcitonin and C-reactive protein for evaluating pulmonary bacterial infection in patients with lupus erythematosus.

Authors:  Jing Gao; Lei Zhang; Xin Zhang; Shi-Long Zhao; Sheng-Yun Liu; Li-Hua Xing
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

7.  Comparison of plasma/serum levels of procalcitonin between infection and febrile disease flare in patients with systemic lupus erythematosus: a meta-analysis.

Authors:  Li-Na Liu; Peng Wang; Shi-Yang Guan; Xiao-Mei Li; Bao-Zhu Li; Rui-Xue Leng; Hai-Feng Pan
Journal:  Rheumatol Int       Date:  2017-10-03       Impact factor: 2.631

8.  Serum procalcitonin for differentiating bacterial infection from disease flares in patients with autoimmune diseases.

Authors:  Kowoon Joo; Won Park; Mie-Jin Lim; Seong-Ryul Kwon; Jiyeol Yoon
Journal:  J Korean Med Sci       Date:  2011-09-01       Impact factor: 2.153

9.  The utility of initial procalcitonin and procalcitonin clearance for prediction of bacterial infection and outcome in critically ill patients with autoimmune diseases: a prospective observational study.

Authors:  Yan Shi; Jin-min Peng; Xiao-yun Hu; Yao Wang
Journal:  BMC Anesthesiol       Date:  2015-10-07       Impact factor: 2.217

10.  Diagnostic Value of Procalcitonin in ANCA-Associated Vasculitis (AAV) to Differentiate Between Disease Activity, Infection and Drug Hypersensitivity.

Authors:  K Herrmann; S Schinke; E Csernok; F Moosig; J U Holle
Journal:  Open Rheumatol J       Date:  2015-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.